165 related articles for article (PubMed ID: 18559671)
1. Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots.
Neyman M; Gewirtz J; Poncz M
Blood; 2008 Aug; 112(4):1101-8. PubMed ID: 18559671
[TBL] [Abstract][Full Text] [Related]
2. Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors.
Gewirtz J; Thornton MA; Rauova L; Poncz M
J Thromb Haemost; 2008 Jul; 6(7):1160-6. PubMed ID: 18433455
[TBL] [Abstract][Full Text] [Related]
3. Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.
Lyde RB; Ahn HS; Vo KK; Jarocha DJ; Tkaczynski J; Treffeisen E; Sullivan SK; Camire RM; Sabatino DE; French DL; Poncz M
Blood Adv; 2019 May; 3(9):1368-1378. PubMed ID: 31036722
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy.
Greene TK; Lyde RB; Bailey SC; Lambert MP; Zhai L; Sabatino DE; Camire RM; Arruda VR; Poncz M
J Thromb Haemost; 2014 Dec; 12(12):2102-12. PubMed ID: 25287191
[TBL] [Abstract][Full Text] [Related]
5. Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice.
Baumgartner CK; Mattson JG; Weiler H; Shi Q; Montgomery RR
J Thromb Haemost; 2017 Jan; 15(1):98-109. PubMed ID: 27496751
[TBL] [Abstract][Full Text] [Related]
6. Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same?
Greene TK; Lambert MP; Poncz M
J Genet Syndr Gene Ther; 2011 Nov; Suppl 1(1):. PubMed ID: 24319630
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression.
Wang Y; Mao J; Li L; Xiao B; Ruan Z; Liu Y; Zhang G; Wang D; Mi JQ; Fang C; Xi X; Shi X; Wang J
Thromb Haemost; 2022 May; 122(5):755-766. PubMed ID: 34587639
[TBL] [Abstract][Full Text] [Related]
8. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.
Zhang G; Shi Q; Fahs SA; Kuether EL; Walsh CE; Montgomery RR
Blood; 2010 Aug; 116(8):1235-43. PubMed ID: 20445020
[TBL] [Abstract][Full Text] [Related]
9. Altered bioavailability of platelet-derived factor VIII during thrombocytosis reverses phenotypic efficacy in haemophilic mice.
Damon AL; Scudder LE; Gnatenko DV; Sitaraman V; Hearing P; Jesty J; Bahou WF
Thromb Haemost; 2008 Dec; 100(6):1111-22. PubMed ID: 19132238
[TBL] [Abstract][Full Text] [Related]
10. Clot stability as a determinant of effective factor VIII replacement in hemophilia A.
Leong L; Chernysh IN; Xu Y; Sim D; Nagaswami C; de Lange Z; Kosolapova S; Cuker A; Kauser K; Weisel JW
Res Pract Thromb Haemost; 2017 Oct; 1(2):231-241. PubMed ID: 29713693
[TBL] [Abstract][Full Text] [Related]
11. Platelet activation and hypercoagulability following treatment with porcine factor VIII (HYATE:C).
Freedman J; Mody M; Lazarus AH; Dewar L; Song S; Blanchette VS; Garvey MB; Ofosu FA
Am J Hematol; 2002 Mar; 69(3):192-9. PubMed ID: 11891806
[TBL] [Abstract][Full Text] [Related]
12. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors.
Rubinger M; Houston DS; Schwetz N; Woloschuk DM; Israels SJ; Johnston JB
Am J Hematol; 1997 Oct; 56(2):112-8. PubMed ID: 9326353
[TBL] [Abstract][Full Text] [Related]
13. Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF.
Shi Q; Wilcox DA; Fahs SA; Kroner PA; Montgomery RR
Mol Genet Metab; 2003 May; 79(1):25-33. PubMed ID: 12765843
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
[TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.
Chen Y; Schroeder JA; Chen J; Luo X; Baumgartner CK; Montgomery RR; Hu J; Shi Q
Blood; 2016 Mar; 127(10):1346-54. PubMed ID: 26668132
[TBL] [Abstract][Full Text] [Related]
16. Coagulation potential of immobilised factor VIII in flow-dependent fibrin generation on platelet surfaces.
Doi M; Sugimoto M; Matsui H; Matsunari Y; Shima M
Thromb Haemost; 2013 Aug; 110(2):316-22. PubMed ID: 23636463
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of the effect of elevated factor VIII on the thrombogenic process.
Golder M; Mewburn J; Lillicrap D
Thromb Haemost; 2013 Jan; 109(1):53-60. PubMed ID: 23178924
[TBL] [Abstract][Full Text] [Related]
18. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.
Cai Y; Shi Q
Front Immunol; 2020; 11():964. PubMed ID: 32595633
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment.
Yarovoi HV; Kufrin D; Eslin DE; Thornton MA; Haberichter SL; Shi Q; Zhu H; Camire R; Fakharzadeh SS; Kowalska MA; Wilcox DA; Sachais BS; Montgomery RR; Poncz M
Blood; 2003 Dec; 102(12):4006-13. PubMed ID: 12881300
[TBL] [Abstract][Full Text] [Related]
20. Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII.
Yarovoi H; Nurden AT; Montgomery RR; Nurden P; Poncz M
Blood; 2005 Jun; 105(12):4674-6. PubMed ID: 15731176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
